Rhythm Pharmaceuticals Inc.(RYTM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RYTM Rhythm Pharmaceuticals Inc.

盘前交易 02-10 04:39:13 EST

103.97

+0.36

+0.35%

最高106.30	最低101.83	成交量47.08万
今开103.61	昨收103.61	日振幅4.31%
总市值69.39亿	流通市值55.54亿	总股本6,674万
成交额4,894万	换手率0.88%	流通股本5,342万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RYTM","market":"US","secType":"STK","nameCN":"Rhythm Pharmaceuticals Inc.","latestPrice":103.97,"timestamp":1770670800000,"preClose":103.61,"halted":0,"volume":470786,"delay":0,"changeRate":0.0034745680918830176,"floatShares":53415100,"shares":66736056,"eps":-3.105726,"marketStatus":"盘前交易","change":0.36,"latestTime":"02-10 04:39:13 EST","open":103.61,"high":106.3,"low":101.83,"amount":48937616.2175,"amplitude":0.043143,"askPrice":162.23,"askSize":43,"bidPrice":94.99,"bidSize":4,"shortable":3,"etf":0,"ttmEps":-3.105726,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770733800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1507176000000,"exchange":"NASDAQ","adjPreClose":103.97,"postHourTrading":{"tag":"盘后","latestPrice":103.97,"preClose":103.97,"latestTime":"19:56 EST","volume":4310,"amount":448119.15,"timestamp":1770684978451,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5943282707453437,"impliedVol":0.6899,"impliedVolPercentile":0.816},"requestUrl":"/m/hq/s/RYTM","defaultTab":"news","newsList":[{"id":"2605491286","title":"Rhythm Pharmaceuticals, Inc.盘中异动 大幅下跌5.00%报102.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605491286","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605491286?lang=zh_cn&edition=full","pubTime":"2026-01-24 01:33","pubTimestamp":1769189600,"startTime":"0","endTime":"0","summary":"北京时间2026年01月24日01时33分，Rhythm Pharmaceuticals, Inc.股票出现波动，股价急速跳水5.00%。截至发稿，该股报102.95美元/股，成交量11.1274万股，换手率0.17%，振幅4.87%。Rhythm Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.96%。其相关个股中，Revelation Biosciences, Inc.、Coherus Oncology, Inc.、Collplant Biotechnologies Ltd.涨幅较大，Revelation Biosciences, Inc.、60 Degrees Pharmaceuticals, Inc.、Aditxt, Inc.较为活跃，换手率分别为1152.96%、144.86%、40.35%，振幅较大的相关个股有Briacell Therapeutics Corp C/Wts 26/02/2026、Revelation Biosciences Inc C/Wts 10/01/2027 、Revelation Biosciences, Inc.，振幅分别为60.41%、58.89%、50.33%。Rhythm Pharmaceuticals, Inc.公司简介：Rhythm Pharmaceuticals Inc 是一家商业阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260124013321a6a5e7a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260124013321a6a5e7a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4139","BK4585","RYTM"],"gpt_icon":0},{"id":"1189038633","title":"Rhythm制药公司：Setmelanotide治疗获得性下丘脑肥胖症的补充新药申请PDUFA目标日期定为2026年3月20日","url":"https://stock-news.laohu8.com/highlight/detail?id=1189038633","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189038633?lang=zh_cn&edition=full","pubTime":"2026-01-09 21:08","pubTimestamp":1767964106,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. 近日披露，其针对Setmelanotide治疗获得性下丘脑肥胖症所提交的补充新药申请，已获得美国食品药品监督管理局设定的处方药使用者付费法案目标日期，定于2026年3月20日。\n这一关键时间节点的确立，标志着该疗法在监管审批流程中迈出了重要一步，为公司在罕见代谢疾病领域的研发进展提供了明确的时间表。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4585","BK4139","BK4588"],"gpt_icon":0},{"id":"1184614665","title":"Rhythm Pharmaceuticals公布探索性第二阶段试验的初步数据，显示Setmelanotide在Prader-Willi综合症中展现了积极的疗效信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1184614665","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184614665?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:32","pubTimestamp":1765456337,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals公布探索性第二阶段试验的初步数据，显示Setmelanotide在Prader-Willi综合症中展现了积极的疗效信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"1103258053","title":"Rhythm Pharmaceuticals Inc.：安全性和耐受性结果与Setmelanotide公认的临床特征一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1103258053","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103258053?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:32","pubTimestamp":1765456335,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.：安全性和耐受性结果与Setmelanotide公认的临床特征一致","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","RYTM","BK4585","BK4139"],"gpt_icon":0},{"id":"1168371881","title":"Rhythm Pharmaceuticals将公布探索性第二阶段临床试验中Setmelanotide在普拉德-威利综合症中的初步数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1168371881","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168371881?lang=zh_cn&edition=full","pubTime":"2025-12-11 05:05","pubTimestamp":1765400748,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals将公布探索性第二阶段临床试验中Setmelanotide在普拉德-威利综合症中的初步数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4585","RYTM"],"gpt_icon":0},{"id":"2585317281","title":"Rhythm Pharmaceuticals, Inc.跌2.13% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2585317281","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585317281?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:31","pubTimestamp":1763735513,"startTime":"0","endTime":"0","summary":"北京时间2025年11月21日22时31分，Rhythm Pharmaceuticals, Inc.股票出现波动，股价大幅下挫2.13%。截至发稿，该股报98.52美元/股，成交量2.9421万股，换手率0.04%，振幅0.17%。Rhythm Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.19%。其相关个股中，Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 、Osr Holdings, Inc.、Sangamo Therapeutics, Inc.涨幅较大，Osr Holdings, Inc.、Telomir Pharmaceuticals, Inc.、Psyence Biomedical Ltd.较为活跃，换手率分别为30.70%、12.52%、10.86%，振幅较大的相关个股有Sangamo Therapeutics, Inc.、Osr Holdings, Inc.、Cue Biopharma, Inc.，振幅分别为21.25%、11.60%、11.08%。Rhythm Pharmaceuticals, Inc.公司简介：Rhythm Pharmaceuticals Inc 是一家商业阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511212231539777db1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511212231539777db1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4139","RYTM","BK4588"],"gpt_icon":0},{"id":"1123883252","title":"节奏制药宣布FDA延长针对获得性下丘脑肥胖患者的IMCIVREE（setmelanotide）审核期限","url":"https://stock-news.laohu8.com/highlight/detail?id=1123883252","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123883252?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:11","pubTimestamp":1763572311,"startTime":"0","endTime":"0","summary":"11月7日 - 节奏制药公司宣布，FDA已延长针对获得性下丘脑肥胖患者的IMCIVREE®（setmelanotide）的审核期限。FDA设定了更新后的PDUFA目标日期为2026年3月20日。FDA在10月要求对获得性下丘脑肥胖的3期试验的有效性数据进行额外的敏感性分析。此次重大修订并未包含任何与setmelanotide的安全性或生产相关的信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4585","RYTM"],"gpt_icon":0},{"id":"1174636319","title":"Rhythm Pharmaceuticals股价在盘前下跌3.5%，因美国FDA延长对其脑损伤相关肥胖药物的审查","url":"https://stock-news.laohu8.com/highlight/detail?id=1174636319","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174636319?lang=zh_cn&edition=full","pubTime":"2025-11-07 21:38","pubTimestamp":1762522702,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals股价在盘前下跌3.5%，因美国FDA延长对其脑损伤相关肥胖药物的审查。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"1196060143","title":"Rhythm Pharmaceuticals Inc.: 重大修订未涉及Setmelanotide的安全性或生产信息","url":"https://stock-news.laohu8.com/highlight/detail?id=1196060143","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196060143?lang=zh_cn&edition=full","pubTime":"2025-11-07 20:36","pubTimestamp":1762518986,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.: 重大修订未涉及Setmelanotide的安全性或生产信息","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","RYTM"],"gpt_icon":0},{"id":"1128479106","title":"Rhythm Pharmaceuticals：10月FDA要求对获得性下丘脑肥胖症三期试验的疗效数据进行额外敏感性分析","url":"https://stock-news.laohu8.com/highlight/detail?id=1128479106","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128479106?lang=zh_cn&edition=full","pubTime":"2025-11-07 20:36","pubTimestamp":1762518981,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals：10月FDA要求对获得性下丘脑肥胖症三期试验的疗效数据进行额外敏感性分析","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4585","RYTM"],"gpt_icon":0},{"id":"1134985244","title":"Rhythm Pharmaceuticals宣布FDA延长Imcivree®（Setmelanotide）对获得性下丘脑肥胖患者审查期限","url":"https://stock-news.laohu8.com/highlight/detail?id=1134985244","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134985244?lang=zh_cn&edition=full","pubTime":"2025-11-07 20:32","pubTimestamp":1762518742,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals宣布FDA延长Imcivree®（Setmelanotide）对获得性下丘脑肥胖患者审查期限","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","RYTM","BK4588"],"gpt_icon":0},{"id":"1106824522","title":"Rhythm Pharmaceuticals在加拿大五个省份及联邦非保险健康福利计划下宣布Imcivree® (Setmelanotide)的公共报销","url":"https://stock-news.laohu8.com/highlight/detail?id=1106824522","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106824522?lang=zh_cn&edition=full","pubTime":"2025-11-06 05:05","pubTimestamp":1762376731,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals在加拿大五个省份及联邦非保险健康福利计划下宣布Imcivree® (Setmelanotide)的公共报销","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","RYTM","BK4588"],"gpt_icon":0},{"id":"2518276046","title":"Rhythm Pharmaceuticals, Inc.盘中异动 早盘快速下挫5.01%报48.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518276046","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518276046?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:30","pubTimestamp":1741617055,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时30分，Rhythm Pharmaceuticals, Inc.股票出现异动，股价大幅下挫5.01%。Rhythm Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.15%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3457.49%、730.68%、517.45%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.，振幅分别为41.36%、40.33%、40.24%。Rhythm Pharmaceuticals, Inc.公司简介：Rhythm Pharmaceuticals Inc 是一家生物制药公司，从事罕见病治疗方法的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223055964044b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223055964044b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4139","RYTM","BK4585"],"gpt_icon":0},{"id":"2517456009","title":"大摩：假定Rhythm Pharmaceuticals(RYTM.US)增持评级, 目标价由72.00美元调整至72.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517456009","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517456009?lang=zh_cn&edition=full","pubTime":"2025-03-08 01:53","pubTimestamp":1741369983,"startTime":"0","endTime":"0","summary":"大摩：假定Rhythm Pharmaceuticals(RYTM.US)增持评级, 目标价由72.00美元调整至72.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08015348605007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RYTM"],"gpt_icon":0},{"id":"2517404949","title":"Stifel：重申Rhythm Pharmaceuticals(RYTM.US)买入评级, 目标价78.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517404949","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517404949?lang=zh_cn&edition=full","pubTime":"2025-03-06 02:01","pubTimestamp":1741197678,"startTime":"0","endTime":"0","summary":"Stifel：重申Rhythm Pharmaceuticals(RYTM.US)买入评级, 目标价78.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06020148550854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RYTM"],"gpt_icon":0},{"id":"2516480445","title":"Rhythm Pharmaceuticals, Inc.2024财年实现净利润-2.61亿美元，同比减少41.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516480445","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516480445?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:00","pubTimestamp":1740931238,"startTime":"0","endTime":"0","summary":"3月3日，Rhythm Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-2.61亿美元，同比减少41.08%；其中营业收入为1.30亿美元，同比增加67.89%，每股基本收益为-4.34美元。机构评级：截至2025年3月3日，当前有11家机构对Rhythm Pharmaceuticals, Inc.目标价做出预测，其中目标均价为74.73美元，其中最低目标价为60.00美元，最高目标价为94.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000058abe4aca5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000058abe4aca5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RYTM"],"gpt_icon":0},{"id":"2514733235","title":"加拿大投资银行集团：维持Rhythm Pharmaceuticals(RYTM.US)评级，由买入调整至买入评级, 目标价由80.00美元调整至81.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514733235","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514733235?lang=zh_cn&edition=full","pubTime":"2025-02-28 04:11","pubTimestamp":1740687119,"startTime":"0","endTime":"0","summary":"加拿大投资银行集团：维持Rhythm Pharmaceuticals(RYTM.US)评级，由买入调整至买入评级, 目标价由80.00美元调整至81.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28041148442125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RYTM"],"gpt_icon":0},{"id":"1168826920","title":"异动解读 | Rhythm Pharmaceuticals公布2024年Q4财报出色 盘中股价大涨5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168826920","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168826920?lang=zh_cn&edition=full","pubTime":"2025-02-27 02:06","pubTimestamp":1740593190,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. (RYTM)今日盘中大涨5.01%，引起了市场的广泛关注。\n\n公司发布的2024年第四季度财报显示营收实现4183万美元，超出市场预期的3848万美元。公司每股亏损0.72美元，则符合了市场对亏损0.73美元的预期。\n\n从财报数据看，公司营收同比大增72.61%，业绩优于市场预期。因此公司财报出色是导致今日股价上涨的主要原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RYTM"],"gpt_icon":0},{"id":"2514145866","title":"Rhythm Pharmaceuticals, Inc.盘中异动 大幅拉升5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514145866","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514145866?lang=zh_cn&edition=full","pubTime":"2025-02-27 02:05","pubTimestamp":1740593153,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日02时05分，Rhythm Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.00%。Rhythm Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.40%。其相关个股中，Enveric Biosciences, Inc.、Pds Biotechnology Corporation、Renovaro Inc.涨幅较大，Enveric Biosciences, Inc.、Aeon Biopharma, Inc.、Organovo Holdings, Inc.较为活跃，换手率分别为6389.14%、258.52%、239.59%，振幅较大的相关个股有Enveric Biosciences, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Pds Biotechnology Corporation，振幅分别为194.07%、49.18%、44.44%。Rhythm Pharmaceuticals, Inc.公司简介：Rhythm Pharmaceuticals Inc 是一家生物制药公司，从事罕见病治疗方法的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227020553abde1c3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227020553abde1c3e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RYTM","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2514831857","title":"Rhythm Pharmaceuticals(RYTM.US)：2024年Q4财报实现营收4183万美元，前值为2423.4万美元，预期值为3848万美元；每股收益为-0.72美元，前值为-0.70美元，预期值为-0.73美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514831857","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514831857?lang=zh_cn&edition=full","pubTime":"2025-02-26 20:11","pubTimestamp":1740571870,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals(RYTM.US)：2024年Q4财报实现营收4183万美元，前值为2423.4万美元，预期值为3848万美元；每股收益为-0.72美元，前值为-0.70美元，预期值为-0.73美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26201148410993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RYTM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rhythmtx.com","stockEarnings":[{"period":"1week","weight":-0.0461},{"period":"1month","weight":0.0292},{"period":"3month","weight":0.0412},{"period":"6month","weight":0.0624},{"period":"1year","weight":0.7568},{"period":"ytd","weight":-0.0287}],"compareEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":-0.0002},{"period":"3month","weight":0.016},{"period":"6month","weight":0.0761},{"period":"1year","weight":0.1551},{"period":"ytd","weight":0.0176}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Rhythm Pharmaceuticals, Inc.是一家特拉华州的公司，成立于2013年2月。该公司是一家全球性、商业阶段的生物制药公司，致力于改变患有罕见神经内分泌疾病的患者及其家人的生活。该公司专注于推进黑皮质素-4受体激动剂，包括他们的主要资产IMCIVREE，作为一种精准药物，旨在治疗由罕见的MC4R通路疾病引起的食欲亢进和严重肥胖。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.051908},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.036776},{"month":3,"riseRate":0.125,"avgChangeRate":-0.055987},{"month":4,"riseRate":0.625,"avgChangeRate":0.023443},{"month":5,"riseRate":0.25,"avgChangeRate":-0.062002},{"month":6,"riseRate":0.5,"avgChangeRate":0.046517},{"month":7,"riseRate":0.5,"avgChangeRate":0.281728},{"month":8,"riseRate":0.75,"avgChangeRate":0.239414},{"month":9,"riseRate":0.375,"avgChangeRate":-0.040591},{"month":10,"riseRate":0.375,"avgChangeRate":-0.015139},{"month":11,"riseRate":0.777778,"avgChangeRate":0.136999},{"month":12,"riseRate":0.555556,"avgChangeRate":0.041318}],"exchange":"NASDAQ","name":"Rhythm Pharmaceuticals Inc.","nameEN":"Rhythm Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rhythm Pharmaceuticals Inc.(RYTM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Rhythm Pharmaceuticals Inc.(RYTM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Rhythm Pharmaceuticals Inc.,RYTM,Rhythm Pharmaceuticals Inc.股票,Rhythm Pharmaceuticals Inc.股票老虎,Rhythm Pharmaceuticals Inc.股票老虎国际,Rhythm Pharmaceuticals Inc.行情,Rhythm Pharmaceuticals Inc.股票行情,Rhythm Pharmaceuticals Inc.股价,Rhythm Pharmaceuticals Inc.股市,Rhythm Pharmaceuticals Inc.股票价格,Rhythm Pharmaceuticals Inc.股票交易,Rhythm Pharmaceuticals Inc.股票购买,Rhythm Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rhythm Pharmaceuticals Inc.(RYTM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Rhythm Pharmaceuticals Inc.(RYTM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}